A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances.

ABSTRACT:

Purpose

Dim light vision disturbances (DLD) comprise a wide range of symptoms affecting the quality of vision at low illumination including glare, halos, and starbursts. This exploratory study investigated 1.0% phentolamine mesylate ophthalmic solution (PMOS) as a treatment to improve vision and image quality for patients with DLD.

Methods

In this placebo-controlled, randomized, double-masked clinical trial, 24 adult patients with severe DLD were randomized in a 2:1 ratio to receive either one dose of PMOS or placebo. Subjects were eligible if they reported experiencing severe night vision difficulty that was not eliminated by distance spectacle correction and scored ≥0.3 log units below the normal range of contrast sensitivity assessed under mesopic conditions with glare at

SUBMITTER: Pepose J 

PROVIDER: S-EPMC9548101 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature